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EZH2/CDK6/tumorigenicity/TCGADeregulation of microRNAs (miRNAs) is implicated in tumor progression. We attempt to indentify the tumor
suppressive miRNA not only down-regulated in glioblastoma multiforme (GBM) but also potent to inhibit the
oncogene EZH2, and then investigate the biological function and pathophysiologic role of the candidate
miRNA in GBM. In this study, we show that miRNA-138 is reduced in both GBM clinical specimens and cell
lines, and is effective to inhibit EZH2 expression. Moreover, high levels of miR-138 are associated with long
overall and progression-free survival of GBM patients from The Cancer Genome Atlas dataset (TCGA) data
portal. Ectopic expression of miRNA-138 effectively inhibits GBM cell proliferation in vitro and tumorigenicity
in vivo through inducing cell cycles G1/S arrest. Mechanism investigation reveals that miRNA-138 acquires
tumor inhibition through directly targeting EZH2, CDK6, E2F2 and E2F3. Moreover, an EZH2-mediated signal
loop, EZH2-CDK4/6-pRb-E2F1, is probably involved in GBM tumorigenicity, and this loop can be blocked by
miRNA-138. Additionally, miRNA-138 negatively correlates to mRNA levels of EZH2 and CDK6 among GBM
clinical samples from both TCGA and our small amount datasets. In conclusion, our data demonstrate a
tumor suppressive role of miRNA-138 in GBM tumorigenicity, suggesting a potential application in GBM
therapy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Glioblastoma multiforme (GBM), with characteristics of high
proliferation and inﬁltrative invasion, is the most common and
aggressive form of malignant brain tumors, associated with poor
prognosis [1,2]. However, the mechanism and effective therapies for
malignant GBM remain elusive. MicroRNAs (miRNAs or miRs) are
a family of endogenous small non-coding RNAs that play key roles
in post-transcriptional gene regulation through targeting protein-
encoding mRNAs [3,4]. Many miRNAs have been conﬁrmed to be
aberrantly deregulated in diverse human cancers and therefore
involved in tumorigenesis [4]. During tumor development and
progression, down-regulated miRNAs in tumors are usually recognizedSun Yat-senMemorial Hospital,
, Guangzhou 510120, China.
.
.V. Open access under CC BY license.to act as tumor suppressors, whereas up-regulated miRNAs in tumors
exert functions as oncogenes [5,6].
Accumulated evidences demonstrate that a pool of miRNAs is as
well involved in gliomagenesis through modulating their target genes
implicated in multiple biological processes, including cell proliferation,
cell cycle, apoptosis, invasion and migration. For example, the down-
regulatedmiR-7 is ﬁrst to show to inhibit glioblastoma cell proliferation
and migration by directly targeting EGFR, IRS1/2 [7] and Raf1 [8].
Another reduced miRNA in glioma, miR-326, is found to not only
promote glioblastoma cell apoptosis and suppress glioma cell tumorige-
nicity in vivo by modulating Notch1/2 [9] but also reduce glioblastoma
and glioma stem cell growth, cellular invasion, metabolic activity by in-
hibition of PKM2 [10]. Likewise, knockdown of up-regulated miRNA in
glioblastoma is also beneﬁcial for tumor control. MiR-10b is augmented
in glioblastoma, and interference of miR-10b induces glioma cell
cycle arrest and apoptosis, which is obtained from increase of target
genes CDKN1A, CDKN2A and Bim [11]. All these studies suggest a po-
tential future of miRNAs in glioblastoma therapy. Although tumor
suppressive roles of multiple miRNAs have been observed in glio-
blastoma, however, efﬁcacy of tumor inhibition is probably different
among miRNAs, which receive less attention. As a result, we attempt
to deﬁne the tumor suppressive miRNAs not only down-regulated in
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gene, enhancer of zeste homolog 2 (EZH2), which has been validated
to extensively participate in gliomagenesis [12–14].
EZH2 possesses the histone methyltransferase activity and can
lead to gene silence through methylating histones [15,16]. EZH2 is
over-abundant in a broad range of human malignancies including
GBM, and contributes to tumor proliferation and cell cycle control
[12,16,17]. The Cyclin-dependent kinase 4 and 6 (CDK4/6) are
critical regulators of cell cycle G1/S transition and are specialized to
phosphorylate and inactivate the cell cycle controller Retinoblastoma
protein (Rb) [18]. Inactivation of Rb (phosphorylated Rb) in cancer
cells results in the deregulation of the transcription factor E2F1,
which controls the expression of genes involved in cell cycle and
proliferation [19]. Actually, alternation of the CDK4/6-pRb-E2F1
pathway has been identiﬁed in the majority of human malignancies
including GBM [19,20]. However, whether knockdown of oncoprotein
EZH2 could trigger inactivation of CDK4/6-pRb-E2F1 pathway
subsequently affecting GBM tumorigenicity remains unknown.
Additionally, it is exhibited that the transcription factor E2F1 is able to
drive EZH2 transcription [21]. Therefore, we come to the hypothesis
that an EZH2-mediated signal loop, EZH2-CDK4/6-pRb-E2F1 is
involved in gliomagenesis, and this signal loop could be suppressed
by the candidate miRNA.
Here, we ﬁnd out that miR-138 is the miRNA that is reduced in
GBM samples and potent to inhibit EZH2 expression. Moreover,
high levels of miR-138 are associated with extended survival of
GBM patients. Functionally, over-expression of miR-138 is able to
effectively inhibit glioblastoma tumor growth through directly
targeting EZH2, CDK6, E2F2 and E2F3. Importantly, the tumor
suppressive potency of miR-138 is obtained by inhibition of a potential
EZH2-CDK4/6-pRb–E2F1 signal loop.
2. Materials and methods
2.1. GBM specimens
Fresh tumor specimens from 25 patients with GBM and non-
neoplastic brains (NNBs) tissues from 14 patients without glioma
were collected in the Department of Neurosurgery, Sun Yat-sen
Memorial Hospital of Sun Yat-sen University. All the GBM tissues
have been pathologically conﬁrmed. Collected tissues for RNA
detecting were immediately snap-frozen in liquid nitrogen and
stored at −80 °C, while tissues for immunohistochemistry were
ﬁxed in 10% formalin and embedded in parafﬁn. The study was
approved by our institutes' ethical committee and all patients gave
informed consent.
2.2. TCGA dataset and patient information
MiRNA-138 and corresponding gene expression dataset and
the corresponding clinical data for glioblastoma samples were
downloaded from The Cancer Genome Atlas (TCGA) data portal
(https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) and analyzed as
described in Supplementary material.
2.3. Cell lines and culture
The normal human astrocytes (NHA)were purchased fromScienCell
Research Laboratories and cultured according to the manufacturer's
instructions. The human GBM cell lines U87MG, U251MG, A172, T98G,
U118 and SHG-44 were obtained from China Academia Sinica cell
repository, Shanghai, China. All cell lines were cultured in Dulbecco's
modiﬁed Eagle's medium (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen) in a humidiﬁed atmosphere containing 5%
CO2 at 37 °C without antibiotics.2.4. Plasmid construction and miRNA/siRNA transfection
Details of plasmid construction (primers were provided in
Supplementary Table 1) and miRNA/siRNA transfection were described
in Supplementary material.
2.5. Cell viability and EdU incorporation assays
Cell viability and EdU incorporation assays were performed
according to themanufacturer' protocol, as described in Supplementary
material.
2.6. In vivo tumorigenicity assay
Female BALB/c nude mice aged 4–5 weeks were purchased from
Laboratory Animal Center of the Sun Yat-sen University. All animal
experimental procedures were performed under the approval of
the Institutional Animal Care and Use Committee of the Sun
Yat-sen University. Two nude mouse models of GBM xenograft tu-
mors were established and details were described in Supplementary
material.
2.7. Cell cycle analysis
Cell cycle distribution analysis was performed by ﬂow cytometry
(FCM; BD) as described in Supplementary material.
2.8. Dual luciferase reporter assays
For dual luciferase reporter assays, miRNAs and EZH2/CDK6/E2F2/
E2F3 wild/mutant 3′-UTR plasmids were co-transfected in U87 cells
for 48 h and then luciferase assays were performed using the
dual-luciferase reporter Assay system (Promega) according to the
manufacturer's instructions. All experiments were repeated at least
three times with duplicate samples.
2.9. RNA extraction and quantitative real-time PCR
Total RNA and quantitative real-time PCR (qPCR) was performed
according to conventional protocol and as described in Supplementary
material (primers were provided in Supplementary Table 1).
2.10. Immunohistochemistry and Western blotting
Immunohistochemistry (IHC) and Western blot analysis were
carried out according to conventional protocol and as described in
Supplementary material.
2.11. Statistical analysis
Quantitative data were expressed as mean ± SEM. Statistical
analysis was performed with the SPSS13.0 software (version 13.0;
SPSS Inc.) using two-tailed Student's t test or one-way analysis of
variance for experiments with more than two subgroups. Survival
analysis was carried out with the Kaplan–Meier method and the
survival curve was generated by GraphPad Prism (version 5.04;
GraphPad Software, Inc.). Correlation analysis was made by using
two-tailed Pearson correlation coefﬁcient. p b 0.05 was considered
statistically signiﬁcant.
3. Results
3.1. MiR-138 was potent to target EZH2 mRNA in human glioblastoma
Given the importance of EZH2 in GBM progression, we tried to
identify a down-regulated miRNA in glioblastoma acting as a tumor
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miRanda, PICTAR5, miRWalk and TargetScan, we predicted 231
miRNAs targeting EZH2 3′-UTR (Supplementary Table 2). Then, we
reviewed 60 down-regulated miRNAs in GBM according to microarray
data in publications (Supplementary Table 3). Next, we integrated the
lists of miRNAs in two supplementary tables and produced a new list
of 13 miRNAs that were not only predicted to target EZH2 but also
were conﬁrmed down-regulated in GBM (Supplementary Table 3).
Finally, using luciferase activity assays, miR-98, miR-101, miR-137,
miR-138 and miR-323 were shown to decrease luciferase activities by
almost 50% relative to NC. Notably, miR-138 reduced the luciferaseFig. 1.MiR-138 was potent to target 3′-UTR of EZH2 mRNA and reduced in GBM cell lines and
target EZH2 3′-UTR were co-transfected with psiCHECK2-EZH2 3′-UTR plasmids into U87
reporter analysis. Data was a summary of 2 independent experiments and each was perform
in GBM cell lines U87, U251 and A172, T98G, U118 and SHG-44. The NHA cell line an
down-regulated in GBM specimens (n = 25) compared with NNBs (n = 14) as determin
were associated with high miR-138 expression at different stratiﬁcations. D1: High miR-1
D2 and D3: High levels of miR-138 were associated with longer OS and PFS from a 263 pati
of miR-138 signiﬁcantly correlated with extended PFS of GBM patients. The Log-rank test p
expression GBM patients was indicated. *, p b 0.05 vs NC; **, p b 0.01 vs NC; ***, p b 0.001activity to 34.5% compared with NC, indicating a strong potency of
miR-138 on inhibiting EZH2 expression in GBM (Fig. 1A).
3.2. Expression levels of miR-138 were reduced in human GBM and were
associated with survival of GBM patients
Then, expression levels of miR-138 were assessed both in GBM cell
lines and clinical samples. Initially, real-time qPCR analysis conﬁrmed
that expression levels of miR-138 were signiﬁcantly reduced in all
GBMcell lines compared toNNB samples (Fig. 1B). Secondly, expression
levels of miR-138 in 25 GBM and 14 NNB specimens were analyzed,specimens. A. Mimics of miRNAs that were down-regulated in glioma and predicted to
glioma cells for 48 h, and then their interactions were determined by dual luciferase
ed in triplicate. B. Expression of miR-138 determined by stem-loop q PCR was reduced
d two human NNB samples were used as controls. C. Expression of miR-138 was
ed by stem-loop qPCR. D. Extended OS and PFS of GBM patients from TCGA dataset
38 was related with long OS among the whole TCGA dataset at the indicated cut-off.
ent dataset. D4: At the stratiﬁcation of patient survival longer than 2 years, high levels
value for the difference between two survival curves for the miR-138-high and -low
vs NNBs.
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demonstrated (Fig. 1C). Moreover, using the TCGA data including 480
GBM samples and 10 normal tissues, we obtained the same trend that
expression of miR-138 was signiﬁcantly decreased in GBM samples in
comparison toNNB samples (6.80 ± 0.76 vs 8.73 ± 0.39, Supplementary
Fig. 1). These results suggested that miR-138 was correlated with GBM
tumorigenesis.
Also, using TCGA clinical information dataset with qualiﬁed
patients, we performed overall survival (OS) and progression-free
survival (PFS) analysis of GBM patients. Using the whole clinical
dataset with 480 patients accompanied by qualiﬁedmiR-138 expression,
we only found that high level of miR-138 was associated with long OS
relative to low level of miR-138 at the stratiﬁcation of n = 65
(high miR-138) as the cut-off (mean survival: 624.7 ± 38.9 vs
425.3 ± 42.2 days; p = 0.0472; Fig. 1D1), although other possible
stratiﬁcation conditions had been tested. Then, Kaplan–Meier
analysis of 263 patients without surgery also showed that patients
with high miR-138 levels were related with longer OS compared
with low levels of miR-138 (mean survival: 752.5 ± 101.6 vs
490.5 ± 47.1 days; p = 0.0347; Fig. 1D2), and that, likewise, high
miR-138 levels were correlated with more extended PFS inFig. 2.MiR-138 suppressed GBM cell viability and proliferation and induced cell cycle arrest
or 96 h after miR-138 or negative control (NC) transfection. B and C. Glioma cell proliferati
after miR-138 or NC transfection (B). The percentage of EdU positive cells was deﬁned as th
and Hoechst-staining cells (blue) were counted in ﬁve visual ﬁelds at 200× magniﬁcation. D
miR-138 or NC transfection. Graphical representation of the cell cycle distributions from
experiments (E). **, p b 0.01 vs NC.comparison to low miR-138 levels (409.3 ± 57.1 vs 254.4 ± 25.3 days;
p = 0.0185; Fig. 1D3). Moreover, at the stratiﬁcation of patient survival
longer than 2 years, high levels of miR-138 signiﬁcantly extended
PFS of GBM patients in relative to low levels of miR-138 (mean survival:
990.5 ± 126.0 vs 609.1 ± 80.2 days; p = 0.0127; Fig. 1D4). Both
expression and survival analysis of miR-138 suggested that miR-138
was associated with in GBM tumor biology.3.3. MiR-138 suppressed GBM cell proliferation and induced cell cycle
arrest in vitro
Next, the impact of miR-138 on GBM cell proliferation was
investigated. First, MTT assays showed that over-expression of
miR-138 in U87 and U251 cells reduced tumor cell viabilities to
approximately maximal 30% relative to NC treatments (Fig. 2A).
Then, cell proliferation was further evaluated by EdU incorporation
assays and the results illustrated that, compared with NC, miR-138
obviously decreased cell proliferation with approximately 50%
reduction of ratios of EdU positive cells in both U87 and U251
cells (Fig. 2B and C).in vitro. A. Glioma cell viability was measured by MTT assay in U87 and U251 cells 48, 72
on was displayed by EdU analysis in U87 (left panel) and U251 (right panel) cells 72 h
e ratio of EdU positive cells to total Hoechst positive cells. The EdU positive cells (red)
and E. Cell cycle distributions were performed by FCM in U87 and U251 cells 72 h after
one experiment (D). Statistic analysis of cell cycle distributions from three repeating
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suppressed GBM cell proliferation, we evaluated cell cycle distributions
using the FCM analysis. After 72 h transfection, both U87 and U251
cells transfected with miR-138 distributed cell cycle arrest of G1/S
progression, with approximately 15% elevation of G1 phase proportion
in U87 cells and 16% of U251 cells compared to NC-transfected cells
(Fig. 2D and E). This result implied that miR-138 suppressed GBM cell
proliferation through blocking G1/S transition of cell cycles.
3.4. MiR-138 suppressed tumor growth of GBM cells in nude mice
Then, two in vivo models were employed to investigate the
suppression of miR-138 on GBM tumor growth. First is the pretreated
xenograft model. U87 cells pre-treated with agomir-138 were
injected subcutaneously into nude mice. Tumor sizes were measured
every 2 days. When tumors size reached the volume of 1000 mm3,
mice were sacriﬁced and tumors were dissected and weighed. After
two weeks of injection, tumors of agomir-NC pretreated group grew
much larger and faster than agomir-138 pretreated group (Fig. 3A).
At the endpoint, the tumor volume of agomir-138 group was
signiﬁcantly smaller than that of agomir-NC group (479.88 ± 150.75
vs 1084.11 ± 264.10 mm3), while the tumor weight of agomir-138
group was almost reduced to half of agomir-NC group (Fig. 3B, C and
D). Moreover, as an indicator of cell proliferation, Ki-67 staining from
an agomir-NC xenograft was more frequent and stronger than that of
agomir-138 treated model (Fig. 3E).
To further conﬁrm this in vivo suppression and assess feasibility
of using miR-138 therapeutics for malignant glioma treatment,
the intratumoral injection model was constructed. SubcutaneousFig. 3. MiR-138 suppressed tumor growth of GBM cells in nude mice. A and B. U87 cells pre
left armpit of the same nude mice. Tumor sizes were measured every 2 days. When tumors
and weighed. The mice and tumor were exhibited (A and B). C. Comparing of tumor weights
volumes from the same group as C. Each data point represents the mean ± SEM of 7 tumo
models (×400 magniﬁcation). F. Agomir-138 suppressed tumor growth in intratumoral i
then cut up into the same square blocks of approximately 2 mm3 and transplanted into righ
injected into xenograft tumor models. Arrows indicated the injection time points. G. Comp
volumes. Each data point represents the mean ± SEM of 5 tumors from intratumoral modexenograft tumors were ﬁrst produced with U87 cells, then cut up
into the same square blocks of approximately 2 mm3 and transplanted
into nude mice. After 9-day incubation, agomir-138 was directly
injected into xenograft tumor models. Even though intratumoral
injections could not achieve uniform spread of miRNA in tumors,
agomir-138 remarkably suppressed the growth of xenografts as
illustrated by reductions of tumor sizes andweight. After approximately
2-week injection, both tumor volume and weight of agomir-NC group
were twice that of agomir-138 group (Fig. 3F, G and H).
3.5. EZH2, CDK6, E2F2 and E2F3 were direct targets of miR-138 in GBM
cells
To ﬁnd out the mechanisms by which miR-138 inhibited
gliomagenesis, we predicted the potential targets of miR-138 using
TargetScan and PicTar algorithms, and EZH2, CDK6, E2F2 and E2F3
were predicted as putative targets of miR-138. Luciferase reporter
vectors containing wild type (mt) and mutant type (mut) 3′-UTR
sequences of EZH2, CDK6, E2F2 and E2F3 were constructed
(Fig. 4A). U87 cells were co-transfected with EZH2, CDK6, E2F2, or
E2F3 mt or mut 3′-UTR vectors and miR-138 mimics for 48 h.
Compared with NC, co-transfection of miR-138 and EZH2 wt 3′-UTR
plasmids resulted in signiﬁcant decrease in luciferase activity
approximately by 65%, with mut1 and mut2 by about 20% and 35%
respectively, while mut1 + 2 almost did not reduce luciferase
activity (Fig. 4B). This result suggested that miR-138 directly
targeted both binding sites within the EZH2 3′-UTR, and that two
miR-138 recognition sites of EZH2 3′-UTR exerted an additive
action. Likewise, co-transfection of miR-138 and CDK6, E2F2 or-treated with agomir-NC or agomir-138 were injected subcutaneously into the right or
size reached the volume of 1000 mm3, mice were sacriﬁced and tumors were dissected
from agomir-138 and agomir-NC pretreated groups (n = 7). D. Growth curve of tumor
rs. E. Examination of levels of Ki-67 by IHC in slice samples from pretreated injection
njection model. Subcutaneous xenograft tumors were ﬁrst produced with U87 cells,
t ﬂanks of nude mice. After 9-day incubation, agomir-138 and agomir-NC were directly
aring of tumor weights from intratumoral models (n = 5). H. Growth curve of tumor
l. *, p b 0.05 vs NC; **, p b 0.01 vs NC.
Fig. 4. EZH2, CDK6, E2F2 and E2F3 were direct targets of miR-138. A. The potential interactions between miR-138 and putative binding sites in 3′-UTRs of EZH2, CDK6, E2F2 and
E2F3 were predicted by PicTar or TargetScan algorisms. Complementarities between miR-138 ‘seed sequence’ and wild-type (wt) 3′-UTRs of putative target genes were exhibited.
Mutant type 1 (mut1) of EZH2 was mutant at binding site 1, mut2 was mutant at binding site 2, and mut1 + 2 were mutant at both binding sites. B. Luciferase activities were
evaluated in U87 cells 48 h after co-transfection of miR-138 mimics and wt or mut 3′-UTR vectors of target genes, with the ﬁnal concentrations of 100 nM for miR-138 mimic
and 10 ng/μl for target genes 3′-UTR vectors. Data were presented as a summary of two separate experiments performed in triplicate. C. Expression of EZH2 and CDK6 protein
was determined by Western blot in U87 and U251 cells 72 h after transfection of miR-138 or NC. β-Actin was used as a loading control. D. Expression of E2F2 and E2F3 was
determined by Western blot in U87 cells 72 h after transfection of miR-138 or NC. GAPDH was used as a loading control. E. Examination of levels of EZH2 by IHC in tumor slice
samples from pretreated injection model (×400 magniﬁcation). **, p b 0.01 vs NC.
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approximately by 50% comparedwith NC, whereas CDK6mut 3′-UTR
was unaffected by simultaneous transfection withmiR-138 (Fig. 4B).
Then, the inhibitory impact of miR-138 on EZH2, CDK6, E2F2
and E2F3 was veriﬁed at protein levels both in vitro and in vivo.
Immunoblot assays conﬁrmed that ectopic expression of miR-138
obviously inhibited expression levels of EZH2, CDK6, E2F2 and
E2F3 in U87 or U251 cells (Fig. 4C and D). In addition, using
tumor tissues from pretreated xenograft models, EZH2 staining
in agomir-138 treated tumor tissues was weaker and less fre-
quent than that of agomir-NC by the IHC assay (Fig. 4E). These data in-
dicated that EZH2, CDK6, E2F2 and E2F3 were authentic targets of
miR-138 in GBM cells.
3.6. EZH2 and CDK6 rescued the function of miR-138 in GBM cells
Because miR-138 was not correlated with E2F2 and E2F3 (see
below 3.8), we performed function-rescuing experiments only
associated with EZH2 and CDK6 to assess whether the tumor
suppressor effect of miR-138 was mediated by repression of EZH2
and CDK6 in GBM cells. Cells were co-transfected with expression
plasmids of EZH2 or CDK6 and miR-138 mimics for 72 h. For
convenience, we just performed one assay to evaluate cell proliferation
for each rescuing experiment. Using MTT assays, EZH2 over-expression
was shown to restore cell viabilities inhibited by miR-138 (Fig. 5A),
while over-expression of CDK6 could restore cell proliferation asinhibited by miR-138 with EdU incorporation assays (Fig. 5C and D).
Meanwhile, consistent with these functional studies, protein levels of
EZH2 and CDK6 inhibited by miR-138 could be recovered by forced
expression of EZH2 or CDK6 (Fig. 5B and E). Collectively, these data
suggested that EZH2 and CDK6 mediated the tumor suppressive role
of miR-138 in glioblastoma cells. In other words, EZH2 and CDK6 were
functional targets of miR-138.
3.7. MiR-138 inhibited the EZH2-CDK4/6-pRb-E2F1 signal loop in GBM
cells
As we know, CDK4/6-pRb-E2F1 pathway is critical for cell
cycle control of G1/S transition [22]. Based on our observations
of glioblastoma cell cycle G1/S arrest and EZH2 inhibition by
miR-138, we hypothesized that miR-138 repressed tumor prolif-
eration through inhibiting EZH2-mediated CDK4/6-pRb-E2F1
pathway.
First, using TCGA gene data, we evaluated relationship between
EZH2 and molecules that were linked with G1/S progression.
Pearson's correlation analysis showed that, in GBM samples, expression
levels of EZH2 were positively and strongly correlated with E2F1 and
E2F3 levels, andweremarginally associatedwith CDK4 and CDK6 levels
with r2 = 0.418 and 0.322 for E2F1 and E2F3, respectively (Fig. 6A),
whereas EZH2 levels were marginally negatively related with E2F2
levels (Supplementary Fig. 2) Likewise, EZH2 levels also exhibited
positive associations with other cell cycle-promoting molecules related
Fig. 5. EZH2 and CDK6 rescued the function of miR-138 in GBM. A. U87 or U251 cells were co-transfected with miR-138 mimic and EZH2 expression plasmids for 72 h. And then cell
viabilities were determined by MTT assay. B. Similar co-transfection as A. Expression of EZH2 protein was analyzed by Western blot. C. U87 or U251 cells were co-transfected with
miR-138 mimic and CDK6 expression plasmids for 72 h. Then, cell proliferation was determined by EdU assay. D. Graphic representation of percentage of EdU positive cells in C.
E. Similar co-transfection as C. Expression of CDK6 protein was analyzed by Western blot. *, p b 0.05 vs NC + empty; **, p b 0.01 vs NC + empty; #, p b 0.01 vs miR-138 + empty.
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and r2 = 0.480 for CCNE1 and CCNE2, respectively (Supplementary
Fig. 2). Moreover, EZH2 was negatively associated with the cell cycleFig. 6.MiR-138 inhibited the EZH2-CDK4/6-pRb-E2F1 signal loop in GBM cells. A. Using TCGA
performed by Pearson's correlation analysis. B. U87 and U251 cells were transfected with
determined by Western blot. β-Actin was used as a loading control. C. U87 and U251 ce
CDK4, CDK6 and pRb were determined by Western blot. β-Actin was used as a loading con
CDK4, EZH2, E2F1 were determined by Western blot (upper). U251 cells were transfected
by Western blot (lower). E. Expression levels of CDK4, pRb, E2F1 and EGFR were determi
F. A diagram of EZH2 mediated signal loop which could be blocked by miR-138 in GBM celinhibitor CDKN1A in GBM samples, even though other cell cycle
inhibitors RB1, P53 and CDKN2A were marginally positively related
with EZH2 levels (Supplementary Fig. 2). These results of correlationgene expression data, relationship between EZH2 and E2F1, E2F3, CDK4 and CDK6 was
siEZH2 for 48 h and then expression levels of EZH2, E2F1, CDK4, CDK6 and pRb were
lls were transfected with siE2F1 for 48 h and then expression levels of E2F1, EZH2,
trol. D. U87 cells were transfected with siCDK4 for 48 h and then expression levels of
with siCDK6 for 48 h and then expression of CDK6, EZH2 and E2F1 were determined
ned by Western blot after 72 h transfection of miR-138 mimics to U87 or U251 cells.
ls. Black box denotes targets of miR-138.
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implicated in glioblastoma cell cycle control.
Subsequently, regulation of EZH2 on expression of cell cycle G1/S
related molecules, such as CDK4, CDK6, pRb and E2F1-3, was evaluated
in glioblastoma cell lines, and the immunoblot assay showed that
expression levels of CDK4, CDK6, pRb and E2F1-3 were signiﬁcantly
reduced after knockdown of EZH2 with effective siEZH2, compared
with NC-transfected cells (Fig. 6B and Supplementary Fig. 3). Together
with correlation analysis above, these in vitro results indicated that
EZH2 took part in cell cycle control and proliferation thoughmodulating
cell cycle related proteins.
Interestingly, it was reported that E2F1 directly bound to EZH2
promoter to drive its transcription [21]. Therefore, we hypothesized
that an EZH2-CDK4/6-pRb-E2F1 signal loop probably existed in
GBM mediating tumor proliferation and cell cycle. To test this idea,
we transfected both U87 and U251 cells with effective siE2F1 due to
the importance of E2F1 other than E2F2 and E2F3, and found that
knockdown of E2F1 induced signiﬁcant reduction of EZH2, CDK4,
CDK6 and pRb proteins (Fig. 6C). To further verify the existence of
this signal loop, cells were treated with effective siRNAs of CDK4 orFig. 7. Correlation analysis between miR-138 and target genes in GBM clinical samples. A.
cells in GBM tissues than NNB samples at the magniﬁcation of 400×. B. Expression levels o
levels of EZH2, CDK6, E2F2 and E2F3 were determined by q-PCR in GBM cell lines. NHA an
reported that miR-138 levels were inversely correlated with EZH2, CDK6 and EGFR mRNA e
NNB.CDK6, and then notable reduction of EZH2 and E2F1 protein was
observed, although knockdown of CDK6 did not show a signiﬁcant
decrease of EZH2 expression (Fig. 6D). Together, our data suggested
that an EZH2-CDK4/6-pRb-E2F1 signal loop existed in glioblastoma
mediating cell cycle and proliferation.
However, CDK4, pRb and E2F1 were predicted not as putative targets
of miR-138, and thus, regulations of miR-138 on these proteins
needed to be assessed. Compared with NC-treated cells, U87 and U251
cells-transfected with miR-138 showed remarkable down-regulation of
CDK4, pRb and E2F1 proteins (Fig. 6E). Notably, Epidermal Growth Factor
Receptor (EGFR) is considered as one biomarker for glioblastoma, and
moreover, it is involved in cell cycle control and proliferation of glioma
[23]. As a result, expression of EGFR was determined in miR-138 treated
glioblastoma cells, and signiﬁcant down-regulation of EGFR was
observed, which further strengthened the inhibitory role of miR-138 in
GBM cell proliferation (Fig. 6E).
Collectively, these results strongly suggested that an EZH2-CDK4/
6-pRb-E2F1 signal loop existed in glioblastoma cell proliferation and
cell cycle control, which could be suppressed by miR-138, leading to
tumor growth inhibition (Fig. 6F).IHC displayed more frequent and stronger nuclear staining of EZH2 and CDK6 positive
f EZH2 and CDK6 were determined by q-PCR in GBM and NNB samples. C. Expression
d two NNB samples were used as controls. D. Two-tailed Pearson's correlation analysis
xpression in 480 GBM and 10 NNB clinical samples from TCGA dataset. ***, p b 0.001 vs
1705S. Qiu et al. / Biochimica et Biophysica Acta 1832 (2013) 1697–17073.8. Levels of miR-138 inversely correlated with expression levels of EZH2
and CDK6 in GBM and NNB samples
Initially, IHC displayed high frequency and strong staining of EZH2
and CDK6 positive cells in GBM specimens than NNB tissue (Fig. 7A).
Next, we evaluated mRNA levels of EZH2 and CDK6 in 25 GBM
specimens by q-PCR, and the results showed that both expression
levels of EZH2 and CDK6 were signiﬁcantly increased in GBM samples
in comparison to NNB tissues (Fig. 7B). Then, relative quantity of
EZH2, CDK6, E2F2 and E2F3 in NHA and GBM cell lines was analyzed
by q-PCR. Compared with NHA or NNB samples, all levels of EZH2,
CDK6, E2F2 and E2F3 were almost increased in GBM cell lines
(Fig. 7C). Then, we sought to ﬁnd out the association between EZH2,
CDK6, E2F2 or E2F3 and miR-138 using TCGA dataset with 480 GBM
and 10 NNB samples with two-tailed Pearson's correlation analysis,
and the results showed that both levels of EZH2 and CDK6 were
negatively correlated with expression of miR-138 (p = 0.008 and
0.002, respectively; Fig. 7D), while E2F2 and E2F3 were marginally
correlated with levels of miR-138 (Supplementary Fig. 4). Meanwhile,
using our small amounts of samples, we found the same trends
between miR-138 levels and EZH2 or CDK6 levels (r2 = 0.303 or
0.341; p b 0.0001; Supplementary Fig. 5). Moreover, an inverse
association was also observed between miR-138 and GBM biological
marker EGFR (Fig. 7D). These results further validated the inhibitory
effects of miR-138 on EZH2, CDK6 and EGFR, although no negative
relationship between E2F2 or E2F3 and miR-138 was observed in
clinical samples.
4. Discussion
It is well demonstrated that deregulation of miRNAs contributes to
carcinogenesis. Hence, restoring deregulated miRNAs maybe leads to
tumor suppression. In our study, we showed that miR-138 was
down-regulated in GBM clinical specimens and cell lines, and that
over-expression of miR-138 effectively suppressed GBM cell prolifer-
ation in vitro and tumorigenicity in vivo. Furthermore, we ﬁrstly con-
ﬁrmed that miR-138 directly bound to 3′-UTR of CDK6, E2F2 and
E2F3. More interestingly, an EZH2-CDK4/6-pRb-E2F1 signal loop
was probably involved in GBM tumorigenicity and miR-138 acquired
tumor inhibitory function through blocking this signal loop.
MiR-138 is involved in a pool of essential biological processes, such
as modulating DNA damage response [24], keratinocyte senescence
[25], regulating dendritic spinemorphogenesis [26],modulating cardiac
morphogenesis during embryonic development [27], and affecting
thermotolerance acquisition [28]. Dysfunction of miR-138 has been
observed in several types of tumors. MiR-138 not only suppresses cell
migration and invasion through targeting RhoC and ROCK2 [29], but
also inhibits epithelial–mesenchymal transition through targeting
VIM, ZEB2 and EZH2 in tongue squamous cell carcinoma [30].
MiR-138 also inhibits expression of HIF-1a, leading to apoptosis
elevation and migration reduction in clear cell renal cell carcinoma
cells [31].Moreover,miR-138 is recently shown to inhibit tumor growth
and block cell cycle arrest of hepatocellular carcinoma (HCC) by
targeting cyclin D3 (CCND3) [32]. Also, it is conﬁrmed to suppress
nasopharyngeal carcinoma tumorigenesis by targeting the cyclin D1
(CCND1) [33]. In addition, miR-138 also takes part in lung cancer
[34,35], thyroid cancer [36] and leukemia [37]. Consistent with the
tumor suppressive role of miR-138 as above, our studies showed that
miR-138 effectively inhibited GBM tumor growth. However, inconsis-
tently, miR-138 did not show signiﬁcant inhibition in cell proliferation
and migration of glioblastoma SF126 cell line, although apparent
reduction of miR-138 has been observed [38]. This discrepancy may
be due to different cell lines of study.
Recently, Chan et al.'s publication reported that miR-138 was
increased in glioma stem cells (GSCs) in comparison to normal neural
stem cells (NSCs), promoted growth and survival of GSCs, and wasassociated with GBM patient recurrence, which was suggested as
prognostic biomarker for GBM patients [39]. However, several
concerns should be noted. One was that GSCs account for minority
of glioma cells, and it was still lacking well-performed approach to
identify and isolate GSCs from glioma samples [40–42]. Second,
almost all microarray and qPCR results showed that miR-138 was
reduced in glioma samples, which was also indirectly conﬁrmed by
Chan et al.'s study that level of miR-138 was down-regulated after
differentiation of GSC cells. Moreover, using clinical information
from TCGA dataset, Chan et al.'s report showed that there was no
signiﬁcant association between OS and miR-138, even though high
miR-138 was prone to be associated with short survival. However,
our analysis demonstrated that highmiR-138 correlated with extended
OS and PFS at several stratiﬁcation conditions. As a result, it may be
more plausible that low miR-138 served as predictor for GBM patients'
outcome. However, these discrepancies suggested the importance of
miR-138 in GBM tumorigenesis.
EZH2 is deregulated in a wide range of cancer types, and has a
crucial role in stem cell maintenance and tumor development [43].
Actually, EZH2 is essential for glioblastoma cancer stem cell mainte-
nance [13]. Several groups showed that tumor cell proliferation and
tumor growth were restricted after deletion of EZH2 expression by
miR-101 [44], miR-26a [45], miR-124 and siEZH2 [33]. Although
EZH2 as a target of miR-138 has been reported in one study associated
with chicken thermal control [28], we ﬁrstly deﬁned that EZH2 was a
functional target of miR-138 in GBM cells and importantly, inverse
correlation of between miR-138 and EZH2 was determined in GBM
specimens and cell lines. Also, CDK6 was identiﬁed as a GBM oncogene
critical inG1/S transition of cell cycle, and depletion of CDK6 suppressed
cell proliferation and viability in GBM cell lines and intracranial
xenografts [18,46]. In our study, CDK6 was ﬁrstly conﬁrmed as a direct
functional target of miR-138, which was similar to that of miR-137 and
miR-124 inhibitedGBMandmedulloblastomaproliferation by targeting
CDK6 [47,48]. Moreover, CDK6 was also inversely correlated with
miR-138 in glioma tissues. Besides, we ﬁrst reported that E2F2 and
E2F3 were direct targets of miR-138 in glioma. However, E2F2 and
E2F3 may not play critical function in miR-138-induced glioma
inhibition, because of that expression of E2F3, not like EZH2, was
much lower in glioma cells compared with NNB samples, and that
E2F2 and E2F3 did not exhibit a negative association with miR-138.
Additionally, EGFR, which is recognized as a key oncoprotein in glioma
[49], was also inhibited by miR-138 and was negatively associated with
miR-138 levels, which could help explain the inhibitory effect of
miR-138 on glioma. Hence, our data revealed that through targeting
EZH2 and CDK6 and other molecules, miR-138 played a critical role in
GBM cell proliferation and tumor growth.
The classical CDK4/6-pRb-E2Fs pathway plays a crucial role in G1/S
transition of cell cycle and actually, alternation of CDK4/6-pRb-E2Fs
pathway is among the most common aberrations found in human
glioma with CDK4/6 over-expression, Rb mutation or silencing, or
E2F1 activation, resulting in deregulated glioma cell proliferation
[18–20,22,50]. Coinciding with G1/S transition arrest of cell cycle,
protein expressions of this pathway were obviously suppressed by
miR-138, similar to siEZH2. However, these proteinswere not predicted
as targets of miR-138 by TargetScan or other software, implicating that
knockdown of EZH2 by miR-138 eventually led to reduction of these
molecules. Moreover, expression of EZH2 was down-regulated after
knockdown of E2F1 and CDK4 by siRNA, although siCDK6 appeared
not to alter EZH2 expression. Meanwhile, correlation analysis of gene
expression from GBM samples showed that EZH2 was signiﬁcantly
associated with cell cycle-promoting molecules (Fig. 6), which strongly
suggested that EZH2 was intrinsically involved in cell cycle control. As
mentioned above, EZH2 acted as an essential downstream mediator of
transcriptional factor E2F1 [21,51]. In addition, it's been considered
that uncontrolled cell growth is an invariable characteristic of
human cancer and that tumor cell proliferation is sustained in the
1706 S. Qiu et al. / Biochimica et Biophysica Acta 1832 (2013) 1697–1707absence of growth factors [52]. Herein, it was rational that there
was an EZH2-mediated CDK4/6-pRb-E2F1 signal loop, promoting
glioma persistent proliferation and progression. Together, our results
suggest that miR-138 acts as tumor suppressor though directly
inhibiting EZH2-CDK4/6-pRb-E2F1 signal loop, blocking which by
miR-138 was beneﬁcial for tumor growth inhibition and cell cycle
control (Fig. 6F).
To date, how EZH2 positively regulates its downstream molecules
remains unclear. Although phosphorylation of EZH2 by Akt and
CDK1/2 probably helps to explain the mechanism [53,54], it makes
sense that EZH2 positively regulates CDK4/6-pRb-E2Fs by silencing
their upstream tumor suppressors. However, expression levels of
CDK4/6 inhibitors, such as CDKN1A, CDKN2A, Rb1 and p53 were not
evaluated in this study. Correlation analysis indicated that EZH2 was
negatively related with CDKN1A expression, which was similar to
one study that EZH2 could repress CDKN2A to promote cell cycle
progression. This may account for reduction of CDK4/6-pRb-E2Fs
signals after EZH2 interference in glioma [21]. Meanwhile, EZH2 was
shown to marginally correlated with P53 level in GBM (Supplementary
Fig. 2), we speculated that EZH2 exerted its tumor inhibitory impact
through P53 independent pathway.
In summary, we investigated the potential role of miR-138 in GBM
tumorigenicity and cell cycle progression. Our ﬁndings suggest that
miR-138 acts as a tumor suppressor in GBM and implicates a potential
application in GBM therapy.
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